Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA CAR T-cells in refractory POEMS, amyloidosis, AIHA, and vasculitis
NCT05263817Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD19/BCMA CAR T-cells in POEMS syndrome (POEMS), amyloidosis, autoimmune hemolytic anemia (AIHA) and 1 more, sponsored by Zhejiang University. Status: unknown.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
POEMS syndrome (POEMS)amyloidosisautoimmune hemolytic anemia (AIHA)vasculitis
Beyond the preview
Go deeper on NCT05263817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263817.